https://pharmavalue.it/la-parole-nel-nuovo-decreto-sui-criteri-negoziali/2021-04-02T12:38:27+02:00https://pharmavalue.it/farmaci-in-sperimentazione-clinica-procedura-di-attivazione-uso-compassionevole/2022-06-30T16:04:36+02:00https://pharmavalue.it/pandemic-the-game-del-perche-si-vince-insieme/2022-06-30T16:02:55+02:00https://pharmavalue.it/primi-commenti-sulle-linee-guida-per-la-compilazione-del-dossier-a-supporto-della-domanda-di-rimborsabilita-e-prezzo-di-un-medicinale/2021-04-02T12:58:54+02:00https://pharmavalue.it/lista-648-96-aifa-come-richiedere-linserimento-di-un-farmaco-indicazione-terapeutica-non-ancora-autorizzati-a-carico-del-ssn/2021-05-20T19:09:58+02:00https://pharmavalue.it/disposizioni-urgenti-materia-di-sperimentazione-dei-medicinali-per-lemergenza-epidemiologica-da-covid-art-40/2021-03-22T12:12:00+01:00https://pharmavalue.it/comitato-etico-unico-nazionale-dellistituto-nazionale-per-le-malattie-infettive-lazzaro-spallanzani/2021-03-22T12:21:16+01:00https://pharmavalue.it/comitato-scientifico-vaccini-covid/2021-03-31T15:57:08+02:00https://pharmavalue.it/comitato-tecnico-scientifico-covid19/2021-03-31T16:21:49+02:00https://pharmavalue.it/linee-guida-aifa-i-nostri-commenti/2022-06-30T16:02:35+02:00https://pharmavalue.it/pasqua-2021-i-nostri-auguri/2022-06-30T15:59:43+02:00https://pharmavalue.it/commissione-lea/2024-04-29T16:16:28+02:00https://pharmavalue.it/consiglio-superiore-di-sanita-membri-di-nomina-non-di-diritto/2021-04-15T17:33:46+02:00https://pharmavalue.it/come-richiedere-e-come-farsi-rimborsare-un-farmaco-accedendo-al-fondo-aifa-5-legge-326/2021-04-07T12:11:09+02:00https://pharmavalue.it/natale-2020-i-nostri-auguri/2022-06-30T16:01:02+02:00https://pharmavalue.it/pasqua-2020-i-nostri-auguri/2022-06-30T16:03:29+02:00https://pharmavalue.it/il-percorso-di-una-procedura-prezzo-e-rimborso-di-un-farmaco-in-italia/2021-04-07T12:11:22+02:00https://pharmavalue.it/sintesi-delle-linee-guida-oms-sulle-politiche-dei-prezzi-dei-farmaci/2022-02-17T12:05:35+01:00https://pharmavalue.it/nuovo-tavolo-tecnico-per-i-pazienti-in-oncologia-oncoematologia-e-cardiologia-al-ministero-della-salute/2021-04-13T12:19:30+02:00https://pharmavalue.it/viviamo-in-tempi-interessanti-market-access/2021-04-13T12:36:45+02:00https://pharmavalue.it/perche-e-importante-farsi-le-domande-giuste/2022-04-04T12:02:50+02:00https://pharmavalue.it/rapporto-vaccini-2019/2021-04-15T17:52:51+02:00https://pharmavalue.it/linformatore-scientifico-e-unantenna-sul-territorio/2021-04-15T18:01:17+02:00https://pharmavalue.it/modifica-dei-requisiti-nazionali-nella-blue-box-dei-medicinali/2021-04-21T10:51:17+02:00https://pharmavalue.it/legge-di-stabilita-2021-e-rimodulazione-dei-tetti-di-spesa-per-la-farmaceutica/2021-04-21T11:13:29+02:00https://pharmavalue.it/comitato-scientifico-per-la-sorveglianza-post-marketing-dei-vaccini-csv-covid19/2021-04-21T11:36:51+02:00https://pharmavalue.it/coronavirus-nuovo-assetto-per-il-comitato-tecnico-scientifico-riduzione-del-numero-dei-componenti-e-nuove-professionalita/2021-04-21T11:52:07+02:00https://pharmavalue.it/gruppo-di-lavoro-per-il-coordinamento-della-strategia-nazionale-di-contrasto-dellantimicrobico-resistenza/2021-04-27T11:53:18+02:00https://pharmavalue.it/perche-questo-quaderno/2022-06-30T16:01:16+02:00https://pharmavalue.it/new%e2%80d7b1fbd15b2d5f9a31caead71c68da468078222f11da9cf4a7a57bc96bd5/2022-04-04T12:23:30+02:00https://pharmavalue.it/highlights-sulle-linee-guida-aifa-per-la-compilazione-del-dossier-prezzi/2021-12-20T11:19:25+01:00https://pharmavalue.it/rapporto-nazionale-2019-luso-degli-antibiotici-in-italia-dellaifa/2021-04-21T18:43:59+02:00https://pharmavalue.it/icmra-coalizione-internazionale-di-regolatori-sulla-salute-di-ogni-regione-del-mondo/2021-04-27T13:02:55+02:00https://pharmavalue.it/i-rapporto-osmed-sullimportazione-parallela-ip-ed-esportazione-dei-medicinali-per-uso-umano-di-aifa/2021-04-27T13:08:56+02:00https://pharmavalue.it/ridefinizione-del-comitato-tecnico-scientifico-cts-covid-19/2021-04-27T13:23:36+02:00https://pharmavalue.it/nuovo-modulo-per-la-richiesta-di-inserimento-di-medicinali-nellelenco-ai-sensi-della-legge-648-96/2021-04-27T15:46:50+02:00https://pharmavalue.it/ern-e-malattie-rare-il-report-dellincisive-health-morning-club-co-organizzato-da-nomos-in-collaborazione-con-pharma-value/2021-12-20T14:49:30+01:00https://pharmavalue.it/il-privilegio-e-invisibile-agli-occhi/2022-06-30T15:55:30+02:00https://pharmavalue.it/chi-sono-i-componenti-del-tavolo-tecnico-per-le-malattie-rare-del-ministero-della-salute/2021-12-20T14:49:16+01:00https://pharmavalue.it/a-breve-il-rinnovo-delle-commissioni-aifa-quali-sono-le-regole/2021-06-28T10:15:48+02:00https://pharmavalue.it/pensierini-la-newsletter/2022-06-30T15:57:12+02:00https://pharmavalue.it/speciale-commissioni-per-la-valutazione-dei-farmaci-le-commissioni-aifa-dal-2004-al-2021/2021-12-20T13:15:11+01:00https://pharmavalue.it/codice-etico-pharma-value/2021-10-18T16:02:08+02:00https://pharmavalue.it/sintesi-del-testo-unico-sulle-malattie-rare/2021-12-20T14:53:14+01:00https://pharmavalue.it/perche-questa-agenda/2022-06-30T15:54:03+02:00https://pharmavalue.it/il-nostro-staff-meeting-a-firenze/2022-06-30T15:54:56+02:00https://pharmavalue.it/nuovi-criteri-di-accesso-al-fondo-5-della-legge-326-2003/2021-12-23T11:38:37+01:00https://pharmavalue.it/ricorso-di-bayer-vs-ministero-della-salute-mef-e-aifa-sui-nuovi-criteri-di-pr-la-sentenza-del-consiglio-di-stato/2022-01-19T11:05:28+01:00https://pharmavalue.it/luso-degli-antibiotici-in-italia-rapporto-nazionale-anno-2020/2022-03-24T15:24:51+01:00https://pharmavalue.it/recupero-delle-risorse-inutilizzate-del-fondo-nazionale-aifa-5/2022-04-22T18:52:19+02:00https://pharmavalue.it/5271-2/2022-05-31T10:30:08+02:00https://pharmavalue.it/analisi-delle-richieste-di-inserimento-dei-farmaci-in-lista-648-96-focus-sulle-valutazioni-della-cts-ginevra-mastroianni-sara-de-franceschi-valeria-viola-pharma-value/2022-05-31T10:59:37+02:00https://pharmavalue.it/lesperienza-di-pharma-value-al-1-congresso-girf-gruppo-ispor-roma-for-future/2022-05-31T11:11:24+02:00https://pharmavalue.it/nuove-autorizzazioni-in-eu-2019-21-unanalisi-a-partire-dallhorizon-scanning-di-aifa/2022-05-31T11:33:06+02:00https://pharmavalue.it/10-anni-di-pharma-value/2022-10-04T16:02:19+02:00https://pharmavalue.it/nuove-procedure-semplificate-in-materia-di-negoziazione-pr/2022-07-22T12:08:39+02:00https://pharmavalue.it/unconventional-team-building/2026-06-18T16:45:08+02:00https://pharmavalue.it/piano-di-attivita-aifa-2022/2022-10-07T16:13:36+02:00https://pharmavalue.it/15-anni-del-master-drmka-un-tedx-su-attivita-regolatorie-e-di-market-access/2022-10-26T14:51:26+02:00https://pharmavalue.it/tempistiche-di-accesso-di-farmaci-e-terapie-avanzate-atmp-per-patologie-ultra-rare/2022-12-01T17:59:59+01:00https://pharmavalue.it/speciale-nomos-pharma-value-n-2-riforma-aifa-scenario-e-prossimi-passaggi/2022-12-13T16:04:13+01:00https://pharmavalue.it/agenda-pharma-value-2023/2023-01-09T19:35:25+01:00https://pharmavalue.it/towards-the-reform-of-governance-of-the-italian-medicines-agency-and-the-single-committee/2023-01-11T17:40:13+01:00https://pharmavalue.it/proposta-di-riforma-normativa-della-648-96-per-un-accesso-rapido-dei-farmaci-orfani/2023-02-02T18:53:50+01:00https://pharmavalue.it/prossimi-passi-per-la-revisione-del-regolamento-dei-farmaci-orfani/2023-03-22T17:19:41+01:00https://pharmavalue.it/dicono-di-noi-primi-risultati-della-richiesta-feedback-dei-nostri-clienti/2023-04-19T12:11:16+02:00https://pharmavalue.it/speciale-commissioni-n3-verso-la-riforma-della-governance-dellagenzia-italiana-del-farmaco-e-la-commissione-unica-a-che-punto-siamo/2023-11-20T12:34:41+01:00https://pharmavalue.it/analisi-di-pharma-value-del-piano-nazionale-malattie-rare-2023-2026-focus-farmaci/2023-05-26T12:08:42+02:00https://pharmavalue.it/special-on-commission-n3/2023-05-29T15:50:57+02:00https://pharmavalue.it/dallhorizon-scanning-al-nuovo-regolamento-hta/2023-06-12T18:37:43+02:00https://pharmavalue.it/pharma-value-al-2-congresso-girf-gruppo-ispor-roma-for-future/2023-07-04T16:20:23+02:00https://pharmavalue.it/aifa-incontra/2023-09-13T19:22:27+02:00https://pharmavalue.it/unconventional-team-building-ii-edizione/2023-09-14T13:24:18+02:00https://pharmavalue.it/nuovo-posticipo-al-rinnovo-commissioni-aifa/2023-09-28T19:54:36+02:00https://pharmavalue.it/new-aifa-regulation/2023-10-09T15:34:31+02:00https://pharmavalue.it/legge-di-bilancio-2024/2023-11-06T22:19:32+01:00https://pharmavalue.it/pharma-value-ad-ispor-europe-2023/2023-11-08T14:59:34+01:00https://pharmavalue.it/evolution-of-the-utilization-of-the-alfa-5-fund-for-orphan-drugs-and-rare-diseases/2023-11-22T17:13:50+01:00https://pharmavalue.it/regional-access-timelines-in-italy-factors-affecting-speed-and-equity/2023-11-27T07:21:53+01:00https://pharmavalue.it/vii-rapporto-annuale-ossfor/2023-12-14T11:12:04+01:00https://pharmavalue.it/agenda-pharma-value-2024/2024-01-12T11:20:08+01:00https://pharmavalue.it/fda-vs-ema-confronto-delle-marketing-authorization-rilasciate-nel-2023/2024-01-15T10:08:32+01:00https://pharmavalue.it/pubblicato-il-decreto-interministeriale-per-nuovo-regolamento-aifa/2024-01-16T10:45:59+01:00https://pharmavalue.it/il-comparatore-per-farmaci-orfani-una-survey-per-identificare-le-sfide-nelle-negoziazioni-di-prezzo-con-aifa/2024-02-06T13:49:33+01:00https://pharmavalue.it/speciale-nuova-aifa-cse-e-riorganizzazione/2024-03-01T10:37:24+01:00https://pharmavalue.it/basta-essere-pazienti/2024-02-23T13:33:39+01:00https://pharmavalue.it/pharma-value_1-anno-da-srl/2024-02-23T14:21:31+01:00https://pharmavalue.it/buon-pasqua-dal-teampharmavalue/2024-03-31T17:02:31+02:00https://pharmavalue.it/commissione-lea-2024/2024-04-29T16:38:50+02:00https://pharmavalue.it/new-aifa-special-cse-and-reorganisation/2024-05-15T13:03:52+02:00https://pharmavalue.it/tavolo-tecnico-revisione-note-aifa-e-pt/2024-09-30T16:33:29+02:00https://pharmavalue.it/pharma-value-al-3-congresso-girf-gruppo-ispor-roma-for-future/2024-06-21T13:01:25+02:00https://pharmavalue.it/speciale-pharma-value-il-nuovo-regolamento-hta/2024-07-09T12:30:19+02:00https://pharmavalue.it/sanzioni-amministrative-aifa/2024-07-22T12:49:12+02:00https://pharmavalue.it/8-orphan-drug-day-la-sfida-dei-comparatori-nei-farmaci-orfani/2024-10-16T17:22:09+02:00https://pharmavalue.it/legge-di-bilancio-2025-innovativita/2025-04-02T17:55:01+02:00https://pharmavalue.it/pharma-value-at-ispor-europe-2024/2024-11-21T11:36:33+01:00https://pharmavalue.it/pharma-value-al-x-congresso-nazionale-ispor-italy-rome-chapter/2024-12-06T11:23:00+01:00https://pharmavalue.it/unesperienza-unica-di-formazione-cross-funzionale-con-astrazeneca/2024-12-10T21:33:46+01:00https://pharmavalue.it/agenda-pharma-value-2025-scrittura-e-contenuti/2025-01-14T14:05:54+01:00https://pharmavalue.it/pharma-value-report-the-new-european-hta-regulation/2025-01-17T17:44:35+01:00https://pharmavalue.it/tavolo-tecnico-di-coordinamento-aifa-regioni/2025-11-04T12:57:23+01:00https://pharmavalue.it/i-criteri-di-valutazione-per-lattribuzione-dellinnovativita-terapeutica/2025-03-28T09:07:15+01:00https://pharmavalue.it/pharmatrend-2025-early-access-programs-its-time-for-a-new-deal/2025-03-31T11:21:47+02:00https://pharmavalue.it/assessment-criteria-for-innovativeness_analysis/2025-04-09T14:10:42+02:00https://pharmavalue.it/la-nuova-strategia-al-2028-della-rete-europea-delle-agenzie-regolatorie/2025-04-14T16:57:39+02:00https://pharmavalue.it/pasqua-2025/2025-04-16T14:35:35+02:00https://pharmavalue.it/aifa-istituisce-il-gruppo-di-lavoro-sul-regolamento-hta-europeo-ue-2021-2282/2025-05-02T10:03:59+02:00https://pharmavalue.it/la-pubblicita-dei-medicinali-in-italia-rapporto-2024/2026-06-25T10:50:41+02:00https://pharmavalue.it/rinnovato-il-comitato-etico-nazionale-per-le-sperimentazioni-cliniche-su-terapie-avanzate/2025-06-06T10:52:02+02:00https://pharmavalue.it/assemblea-farmindustria-2025-trasformazione-globale-life-sciences-strategy-e-industria-farmaceutica-futuro-e-competitivita-dellitalia-nel-mondo/2025-07-04T18:13:03+02:00https://pharmavalue.it/documento-definitivo-sui-criteri-di-valutazione-per-lattribuzione-dellinnovativita-terapeutica/2025-07-23T11:10:52+02:00https://pharmavalue.it/assessment-criteria-for-the-designation-of-therapeutic-innovativeness/2025-08-01T12:19:17+02:00https://pharmavalue.it/verso-un-nuovo-testo-unico-per-la-legislazione-farmaceutica/2025-08-01T12:25:17+02:00https://pharmavalue.it/nuovo-consiglio-superiore-di-sanita-2025-2028/2025-09-02T11:50:46+02:00https://pharmavalue.it/iv-unconventional-team-building-risultati-pianificazione-strategica-e-relazioni/2025-10-06T12:51:56+02:00https://pharmavalue.it/pharma-value-raccontata-dalla-sua-fondatrice-intervista-a-valeria-viola/2026-06-24T13:23:00+02:00https://pharmavalue.it/oggi-ti-presentiamo-la-rubrica-che-racconta-il-team-pharma-value-si-conclude/2025-10-16T11:40:29+02:00https://pharmavalue.it/agenda-pharma-value-2026-il-genio-collettivo/2025-12-29T08:08:42+01:00https://pharmavalue.it/aifa-updates-the-guidelines-for-pricing-and-reimbursement-dossiers-toward-a-fully-hta-based-framework/2026-02-02T19:04:37+01:00https://pharmavalue.it/pharma-value-at-ispor-europe-2025/2026-06-24T13:08:04+02:00https://pharmavalue.it/osservatorio-regional-access-ora/2026-06-11T10:23:58+02:00https://pharmavalue.it/la-geopolitica-del-farmaco-prezzi-potere-e-sicurezza-nelleconomia-globale-3-giugno-2026-a-roma/2026-06-26T17:27:50+02:00https://pharmavalue.it/pharma-value-al-v-congresso-nazionale-girf/2026-06-17T10:56:03+02:00https://pharmavalue.it/presentazione-del-progetto-osservatorio-regional-access-ora/2026-06-25T15:52:48+02:00